Hemostemix Inc · TSXV:HEM
Hemostemix — Investor Presentation (November 2022)
22 slides from Hemostemix's investor presentation, November 2022

Slide 1: Scaleable Autologous Stem Cell Therapeutics
SCALEABLE AUTOLOGOUS STEM CELL THERAPEUTICS FALL 2022 PRESENTATION F Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) © Hemostemix Inc. All Rights Reserved.

Slide 2: Forward-Looking Information
Forward-Looking Information This presentation contains forward looking statements that reflect management’s Actual results, performance and achievement(s) could differ materially from that expectations regarding the future growth and results of operational performance expressed in, or implied by, an

Slide 3: Hemostemix Vision and Mission
Global Business Opportunity Hemostemix Vision and Mission Hemostemix Vision is to be the first, Hemostemix Mission is to deliver at most affordable, autologous stem cell scale the best autologous stem cell therapy company approved to treat therapeutic for cardiomyopathy and other cardiomyopathy. dis

Slide 4: Market Size
Market Size Ischemia Indications Lung Diseases Heart diseases including Angina USD$10.26 Billion in COPD - USD$17.7 Billion – 2021 – growth 7.3% to 2020, growing to USD$10.72 Billion USD in 2026. USD$26.95 to 2027. Source: Research and Markets Source: 360 Research Reports Idiopathic Pulmonary Hypert

Slide 5: The Hemostemix Platform
The Hemostemix Platform ACP NCP- CCP- -01 01 01 Angiogenic Cell Precursor Neuronal Cell Precursor Cardiomyocyte Cell Precursor Neovascularaization at the Rebuilds neuronal site of need (ischemia) pathways Rebuilds Heart following Infarct Angina, Dilated and Homes to site of injury Ischemic Cardiomyo

Slide 6: ACP-01 7-Day, Scalable Process
ACP-01 7-Day, Scalable Process 1 2 3 4 5 6 7 B lood collection Isolation of Culturing and Cell Q uality Control Packaging Administration and shipping SCP d ifferentiation harvesting release tests and shippin g of cells to of cells and batch damaged qualification tissue 6

Slide 7: ACP-01 Clinical Trial History
ACP-01 Clinical Trial History Clinical Trial Pilot Safety/ Phase 1b Safety Phase 2 Safety Safety and Safety and Type of Study Safety and Feasibility and Efficacy and Efficacy Efficacy Efficacy Feasibility Canada and Bangkok Heart Study Location Thailand Hungary Thailand Thailand United States Hospit

Slide 8: Retrospective ACP-01 Cardiomyopathy Study Results
Retrospective ACP-01 Cardiomyopathy Study Results 52 consecutive patients who underwent transcatheter intramyocardial or intracoronary injection of ACP-01 for the treatment of cardiomyopathy were studied. The pre and post-procedure ejection fraction percentage (EF%), were reported from MUGA scan, SP

Slide 9: Cardiomyopathy Study Highlights
Cardiomyopathy The non-ischemic dilated cardiomyopathy patients (n=8), Study Highlights IMPROVED +14.35% improved from 25.94% before treatment to 40.29% at final follow- up, for an overall improvement of 14.35% (p=0.002) at 12 months. IMPROVED For ischemic heart failure alone +8.37% (n=41), LVEF inc

Slide 10: Changes in LVEF
Changes in LVEF Change in LVEF 60 50 Important 40 Overall, upward mobility from one quartile Average LVEF Pretx n=53 to the next quartile was significant 30 Posttx n=52, (p=.0007) for first follow up, and more p=0.0007 significant (p=0.0002) for final follow up. 20 Final n=35, p=0.0002 Three of the

Slide 11: Key Differentiators of ACP-01
Key Differentiators of ACP-01 Non-surgical, enhanced cell therapy Simple, cost-effective treatment for restoring circulation to blood production process starved tissues and organs Scalable Low No Patient Ethical Self-donation, means Risks Concerns Stem cells derived no immune rejection or Ready in d

Slide 12: Unique Properties
Unique Properties Non-surgical, enhanced cell therapy treatment for restoring circulation to blood starved tissues and organs Patented peripheral Created from the ACP-01 are cultured in Sourced, Five patent families, blood-based patients own blood, the patients’ serum, processed and including compos

Slide 13: Scalable Production
Scalable Production A Stepped Approach to Automated Scaled Production and Profitability STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 MANUAL SEMI-AUTO F U L LY AU TO M AT E D 20 batches/mo. 40 batches/mo. 60 batches/mo. 72 batches/mo. 80 batches/mo. 4000 batches/mo. l Team 2 Teams 2 Teams 2 Teams 2 Team

Slide 14: Scalable Production
Scalable Production A Stepped Approach to Batch Cost Reduction and Profitability STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 MANUAL SEMI-AUTO F U L LY AU TO M AT E D 20 batches/mo. 40 batches/mo. 60 batches/mo. 72 batches/mo. 80 batches/mo. 4000 batches/mo. l Team 2 Teams 2 Teams 2 Teams 2 Teams 5 fac

Slide 15: Management & Directors Advisory Board
Management & Advisory Directors Board DAVID H. TSUBOUCHI B.A., J.D., LL.D., D.S.Litt., C.Dir. THOMAS DR. FRASER DR. RONNIE PETER LACEY SMEENK HENDERSON HERSHMAN ICD.D Chairman BA President & of the Board HONORABLE SHEiLA COPPS OC, PC MD, Chief M.D., F.C.C.S. CEO, Co-Founder Medical Officer Director

Slide 16: Scientific Advisory Board Additions
Scientific Advisory Board Additions DR. NADIA GIANNETTI DR. TERRY HEBERT DR. RENZO CECERE Associate Assistant Dean, Director Chief, Division Cardiac Investigator/Professor, McGill Regenerative Surgery, McGill University Department Of Medicine, Medicine McGill University DR. JOHANNES GRILLARI DR. ERN

Slide 17: Share Capital
Share Capital Share capital structure NUMBER EXPIRY as of September 13, 2022 Shares 75,743,035 Warrants (weighted average stock price $0.5014/) 74,692,004 Mar 2023-Apr 2027 Options 6,775,694 Apr 2023-Feb 2027 Fully Diluted (no CD Conversion) 157,210,733 Convertible Debenture 1 ("CD1") 6,250,000 Conv

Slide 18: Takeaways
No signs of toxicity or rejection with ACP 01 autologous stem cells Over 500 Highly patients scalable and treated with quickly ACP 01 since 2003 Takeaways Multiple Little if any indications competing equates to products – $100 billion Hemostemix plus in a class by opportunity itself ACP 01 used for

Slide 19: Contact
THOMAS SMEENK President, CEO, Co-Founder Contact tsmeenk@hemostemix.com +1-905-580-4170 19

Slide 20: Appendix A
Appendix A Dr. Fraser Henderson Sr., CMO Dr. Fraser Henderson is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is Director of The Metropolitan Neurosurgery Group, LLC, Chief of Neurosurgery at Luminis

Slide 21: Appendix A
Appendix A Dr. Ina Sarel, CSO • Over 25 years of stem cell therapy discovery and business experience • Mother of Neural Cell Precursors • VP Product Development, Cellect Biotechnology Oct 2017 - Dec 2019 • Vice President R&D, Hemostemix 2011 - Oct 2017 • Director of R&D, Hemostemix 2008 – 2010 • Dir

Slide 22: Appendix A
Appendix A HONORABLE SHELIA COPPS DAVID H. TSUBOUCHI OC, PC B.A., J.D., LL.D., D.S.Litt., C.Dir. Former Deputy Prime Minister of First Japanese Canadian to be Canada, Minister of Environment, elected to any provincial legislature Minister of Heritage and a senior in Canada and to be appointed as a m
Source: Internet Archive copy of hemostemix.com
More decks from Hemostemix Inc
Investor Presentation (2026)17 slides · Nov 4, 2026
Investor Presentation (2026)23 slides · 2026
Investor Presentation (2025)22 slides · Nov 3, 2025
Investor Presentation (July 2023)23 slides · Jul 5, 2023
Investor Presentation (April 2023)24 slides · April 2023
Investor Presentation (March 2022)18 slides · Mar 29, 2022